National Research Council. The Prevention and Treatment of Missing Data in Clinical Trials. Panel on Handling Missing Data in Clinical Trials. Committee on National Statistics, Division of Behavioral and Social Sciences and Education. Washington, DC: The National Academies Press, 2010.
3.
MorrisonBWCochranCJWhiteJG. Monitoring the quality of conduct of clinical trials: A survey of current practices. Clin Trials2011; 8(3): 342–49.
4.
NeatonJDBartschGEBrosteSKCohenJDSimonNM. A case of data alteration in the Multiple Risk Factor Intervention Trial (MRFIT). The MRFIT Research Group. Control Clin Trials1991; 12(6): 731–40.
5.
European Commission. Health and Consumers Directorate-General. The rules governing medicinal products in the European Union volume 10-guidance documents applying to clinical trials, Version 9.0, Brussels, 2011. Available at: http://ec.europa.eu/health/files/clinicaltrials/ctqa_2011-08.pdf
6.
NeatonJDBabikerABohnhorstM. Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health. Clin Trials2010; 7(6): 705–18.
7.
MontoriVMDevereauxPJAdhikariNK. Randomized trials stopped early for benefit: A systematic review. JAMA2005; 294(17): 2203–09.
8.
FreidlinBKornEL.Stopping clinical trials early for benefit: Impact on estimation. Clin Trials2009; 6(2): 119–25.
9.
HIV Trialists’ Collaborative Group. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: Meta-analyses of the randomised evidence. Lancet1999; 353(9169): 2014–25.
10.
HammerSMSquiresKEHughesMD. Controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med1997; 337: 725–33A.